Walgreens Boots Alliance — Q4 2021 Earnings Presentation
31 slides from Walgreens Boots Alliance's earnings presentation, Oct 14, 2021
Slide 1: Fourth Quarter & Fiscal 2021 Results
Fiscal 2021 Fourth Quarter & Fiscal 2021 Results October 14, 2021 © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 1
Slide 2: Safe harbor and non-GAAP
Safe harbor and non-GAAP Cautionary Note Regarding Forward-Looking Statements: This presentation and the related discussion contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These include, without limitation, any s
Slide 3: WBA Financial Performance
WBA Financial Performance © 2021 Walgreens Boots Alliance, Inc. All rights reserved. 3
Slide 4: FY21 and 4Q financial highlights
FY21 and 4Q financial highlights • Strong finish to the year, exceeded expectations • 4Q continuing operations adj. EPS $1.17, +28.1% above prior year in constant Fx • FY21 continuing operations adj. EPS $4.91, +13.7% above prior year in constant Fx ⎯ Includes 34.6 million doses of COVID-19 vaccines
Slide 5: FY21 and 4Q financial highlights
FY21 and 4Q financial highlights • 4Q results reflected strong execution across the board ⎯ U.S. comparable scripts +8.8%, boosted by COVID-19 vaccines +485bps; 21% share of 4Q vaccinations ⎯ U.S. retail comp sales growth +6.2%, +7.2% excl. tobacco & e. cig ⎯ UK recovery on track and regaining marke
Slide 6: Fiscal year financial highlights
Fiscal year financial highlights Results Reported Fx Constant Fx FY21 $ in millions (except EPS) B/(W) vs. FY20 B/(W) vs. FY20 Sales (continuing) $132,509 + 8.6% + 7.5% Operating income GAAP $2,342 + 138.4% (continuing) Adjusted $5,117 + 8.2% + 7.7% EPS - total GAAP $2.93 + $2.42 Adjusted $5.31 + 11
Slide 7: 4Q financial highlights
4Q financial highlights Results Reported Fx Constant Fx 4Q21 $ in millions (except EPS) B/(W) vs. 4Q20 B/(W) vs. 4Q20 Sales (continuing) $34,262 + 12.8% + 11.8% Operating income GAAP $910 + 49.7% (continuing) Adjusted $1,236 + 22.9% + 22.1% EPS - total GAAP $0.72 + 68.0% Adjusted $1.17 + 14.9% + 13.
Slide 8: United States – financials
United States – financials Continuing operations $ in millions 4Q21 B/(W) vs. 4Q20 FY21 B/(W) vs. FY20 Sales $28,755 + 6.6% $112,005 + 4.0% Adj. gross profit $6,234 + 13.7% $23,759 + 5.5% Adj. SG&A % of sales 17.8% - 1.0%p 17.2% - 0.3%p Adj. operating income $1,230 + 16.4% $5,019 + 5.4% Adj. operati
Slide 9: United States – pharmacy
United States – pharmacy 4Q 4Q FY21 FY21 4Q21 vs. 4Q20 | FY21 vs. FY20 Total Comparable Total Comparable Pharmacy sales + 6.7% + 8.9% + 5.5% + 6.7% Prescriptions + 8.6% + 8.8% + 3.8% + 5.0% • 4Q comparable scripts grew +8.8% boosted by COVID-19 vaccinations +485bps ⎯ 13.5 million COVID-19 vaccinatio
Slide 10: United States – retail
United States – retail 4Q FY21 4Q21 vs. 4Q20 | FY21 vs. FY20 Total retail sales + 6.5% - 0.4% Comparable retail sales + 6.2% + 1.2% • 4Q comp. retail sales +6.2%; excluding tobacco +7.2%, improved sequentially with broad based growth across all categories ⎯ Health and wellness +14.0% driven by late
Slide 11: U.S. operational updates – pharmacy
U.S. operational updates – pharmacy • Continued progress on modernizing pharmacy operating model ⎯ iA Rx automated micro-fulfillment centers currently servicing >800 locations ⎯ On track for nine operational markets by end of FY22 • Village Medical at Walgreens roll-out plans on track ⎯ 52 locations
Slide 12: U.S. operational updates – retail
U.S. operational updates – retail • Customer Engagement Platform learnings continuously enhancing personalized offerings ⎯ myWalgreens membership +13% vs. 3Q21 to ~85m members to date ⎯ Mass personalization boosted 4Q retail sales comps by ~40bps • Omni-channel offerings accelerating ⎯ Digitally ini
Slide 13: International – financials
International – financials Continuing operations Constant Fx Constant Fx $ in millions 4Q21 B/(W) vs. 4Q20 FY21 B/(W) vs. FY20 Sales $5,507 + 52.6% $20,505 + 34.1% Adj. gross profit $1,198 + 32.7% $4,327 + 7.3% Adj. SG&A % of sales 19.2% + 5.7%p 18.8% + 6.5%p Adj. operating income $140 + $129 $466 +
Slide 14: Boots UK – financials
Boots UK – financials 4Q FY21 4Q21 vs. 4Q20 | FY21 vs. FY20 (constant Fx) Pharmacy comp. sales + 11.4% + 5.2% Retail comp. sales + 15.0% + 0.9% • Pharmacy comp. sales +11.4%; driven by pharmacy services • 4Q recovery in retail sales ⎯ Store footfall ~+35% vs. prior year; remains ~-30% below pre-COVI
Slide 15: Boots UK operational updates
Boots UK operational updates • Continued market share gains in beauty ⎯ Boots #1 beauty destination with market share >40% ⎯ Major marketing campaign underpinned strong market share gains ⎯ 44 new brands launched this fiscal year ⎯ Implemented 100th beauty reinvention store during the quarter • Expa
Slide 16: Cash flow
Cash flow B/(W) $ in millions FY21 vs. FY20 Operating cash flow $5,555 $70 Cash capital expenditure ($1,379) ($5) Free cash flow $4,176 $65 • FY21 free cash flow grew by +1.6% versus prior year, +12.1% excluding the adverse 4Q impact from the Pharmaceutical Wholesale divestiture • Strong operating p
Slide 17: Endnotes
Endnotes • Unless otherwise noted, all prior year numbers have been recast for continuing operations. Refer to WBA's Current Report on Form 8-K filed on March 31, 2021. • Please see appendix for reconciliations of non-GAAP financial measures and related disclosures ◦ The company presents certain inf
Slide 18: Appendix
Appendix The information on the following pages provides reconciliations of the supplemental non-GAAP financial measures, as defined under SEC rules, presented in this presentation and discussed on the related conference call to the most directly comparable financial measures calculated and presente
Slide 19: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended August 31, Change vs. 4Q20 Twelve months ended August 31, Change vs. FY20 2021 2020 Amount Percent 2021 2020 Amount Percent
Slide 20: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended August 31, Change vs. 4Q20 Twelve months ended August 31, Change vs. FY20 2021 2020 Amount Percent 2021 2020 Amount Percent
Slide 21: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) NET EARNINGS Three months ended August 31, Change vs. 4Q20 Twelve months ended August 31, Change vs. FY20 2021 2020 Amount Percent 2021 2020 Amount Percent
Slide 22: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) DILUTED NET EARNINGS (LOSS) PER SHARE Three months ended August 31, Change vs. 4Q20 Twelve months ended August 31, Change vs. FY20 2021 2020 Amount Percent
Slide 23: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) 1 Adjustments to equity earnings (loss) in AmerisourceBergen consist of the Company’s proportionate share of non-GAAP adjustments reported by AmerisourceBe
Slide 24: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Three months ended August 31, 2021 Walgreens Boots United States1 International Corporate and Other Alliance, Inc. Sales $ 28,755 $ 5,507 $ — $ 34,262 Gros
Slide 25: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) Three months ended August 31, 2020 (in millions) Walgreens Boots United States1 International Corporate and Other Alliance, Inc. Sales $ 26,967 $ 3,403 $ — $ 30,371 Gros
Slide 26: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) Twelve months ended August 31, 2021 Walgreens Boots United States1 International Corporate and Other Alliance, Inc. Sales $ 112,005 $ 20,505 $ — $ 132,509
Slide 27: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) Twelve months ended August 31, 2020 (in millions) Walgreens Boots United States1 International Corporate and Other Alliance, Inc. Sales $ 107,701 $ 14,281 $ — $ 121,982
Slide 28: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) 1 Operating income (loss) for United States includes equity earnings (loss) in AmerisourceBergen. As a result of the two month reporting lag, operating inc
Slide 29: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) EQUITY EARNINGS (LOSS) IN AMERISOURCEBERGEN Three months ended August 31, Twelve months ended August 31, 2021 2020 2021 2020 Equity earnings (loss) in Amer
Slide 30: Reconciliation of Non-GAAP financial measures
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) ADJUSTED EFFECTIVE TAX RATE Three months ended August 31, 2021 Three months ended August 31, 2020 Earnings before Earnings before Income tax Income tax inc
Slide 31: Free cash flow
Reconciliation of Non-GAAP financial measures Walgreens Boots Alliance, Inc. and Subsidiaries Supplemental Information (unaudited) (in millions) FREE CASH FLOW Three months ended August 31, Twelve months ended August 31, 2021 2020 2021 2020 Net cash provided by operating activities (GAAP) $ 1,245 $
Walgreens Boots Alliance — Q4 2021 Earnings Presentation on 6ix